The FDA has approved ramucirumab (Cyramza) monotherapy for patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/ML and have been previously treated with sorafenib.
Original Article: FDA Approves Second-Line Ramucirumab in AFP-Elevated HCC